Tenosynovial giant cell tumour (TGCT), formally known as pigmented villonodular synovitis (PVNS), arises from the synovium of joints, tendon sheaths, and bursae [1–4]. Although once postulated to be an inflammatory process, TGCT is now considered a true neoplastic disease [4]. It is typically a benign lesion, which has been described to have the capacity to erode cartilage or bone as the disease progresses. They tend to affect individuals in the third to fifth decades of life, with a female preponderance of 2:1 [1, 5, 6]. Translocation of colony-stimulating factor (CSF) gene is frequently involved in this tumour, responsible for proliferation and recruitment of macrophages, which are a predominant cell type seen in TGCT [3, 5, 7].